26 / 31
• n: 110 pts
• Primary EP: DFS after 3rd line (Δ 4 to 7 months, HR 0.57)
• Secundary EP: OS, DFS after 2nd line
COMETS
: irinotecan/cetuximab followed by FOLFOX-4 or the
reverse strategy in mCRC after first-line FOLFIRI/bevacizumab
Cascinu S, et al. EJC 2017
IRINOTECAN-
CETUXIMAB
FOLFOX-4
FOLFOX-4
IRINOTECAN-
CETUXIMAB
wt KRAS mCRC
FOLFIRI-BEV